Skip to main content

Table 2 Odds ratios of starting a RPV- vs. EFV-based regimen from fitting a logistic regression model

From: Observational cohort study of rilpivirine (RPV) utilization in Europe

Factor

Logistic regression estimates of factors associated with initiating RPV vs EFV

Based on 1355 initiations of RPV and 333 initiations of EFV

 

Univariable estimates

Multivariable estimates

Type III p-value

Odds ratio (95% CI)

p-value

Adjusted Odds ratio (95% CI)

p-value

Age/Sex/Race/Weigh

 Age

per 5 years older

1.42 (1.33, 1.52)

 < 0.001

   

 Male

vs. Female

0.68 (0.50, 0.94)

0.020

0.63 (0.34, 1.16)

0.137

 

 White

vs. Non-white

0.99 (0.71, 1.37)

0.936

1.68 (0.87, 3.22)

0.119

 

 Underweight (BMI < 19)

vs. (19 <  = BMI < 25)

0.85 (0.48, 1.51)

0.588

   

 Overweight (25 <  = BMI < 30)

vs. (19 <  = BMI < 25)

1.36 (0.82, 2.26)

0.240

   

 Obese (BMI >  = 30)

vs. (19 <  = BMI < 25)

1.27 (0.55, 2.92)

0.572

   

 BMI unknown

vs. (19 <  = BMI < 25)

0.46 (0.34, 0.63)

 < 0.001

   

Geographical region

     

 < 0.001

 South

vs. West Central

0.92 (0.64, 1.34)

0.679

0.64 (0.33, 1.24)

0.189

 

 North

vs. West Central

0.58 (0.39, 0.84)

0.005

0.45 (0.23, 0.91)

0.025

 

 East Central

vs. West Central

0.52 (0.35, 0.77)

0.001

0.43 (0.21, 0.91)

0.026

 

 East

vs. West Central

0.05 (0.03, 0.09)

 < 0.001

0.11 (0.04, 0.28)

 < 0.001

 

HIV Parameters

 CD4 Cell count

per doubling

1.19 (1.13, 1.25)

 < 0.001

1.37 (1.15, 1.63)

 < 0.001

 

 CD4 Cell count nadir

per doubling

0.96 (0.91, 1.01)

0.119

0.79 (0.67, 0.92)

0.003

 

 HIV viral load

per log10 higher

0.46 (0.42, 0.51)

 < 0.001

0.72 (0.61, 0.84)

 < 0.001

 

HIV Transmission Route

     

 < 0.001

 PWID

vs. MSM

0.52 (0.38, 0.69)

 < 0.001

0.79 (0.43, 1.46)

0.458

 

 Heterosexuals

vs. MSM

0.72 (0.53, 0.99)

0.041

0.46 (0.26, 0.81)

0.007

 

 Other

vs. MSM

0.78 (0.47, 1.29)

0.337

0.56 (0.24, 1.29)

0.173

 

Hepatitis virus coinfection

     

 < 0.001

 HBsAg positive

vs. Negative

0.63 (0.37, 1.08)

0.095

0.84 (0.27, 2.59)

0.766

 

 HBsAg unknown

vs. Negative

0.43 (0.32, 0.58)

 < 0.001

1.49 (0.79, 2.78)

0.214

 

 HCVAb positive

vs. Negative

0.58 (0.45, 0.75)

 < 0.001

   

 HCVAb unknown

vs. Negative

0.30 (0.20, 0.45)

 < 0.001

   

Hypertension/Diabetes/eGFR

 Previous hypertension

vs. None

1.07 (0.74, 1.53)

0.726

1.19 (0.70, 2.03)

0.519

 < 0.001

 Unknown hypertension

vs. None

0.20 (0.15, 0.27)

 < 0.001

0.59 (0.31, 1.11)

0.100

 

 Previous diabetes

vs. None

2.95 (1.26, 6.88)

0.012

1.04 (0.33, 3.27)

0.942

 < 0.001

 Unknown diabetes

vs. None

0.60 (0.47, 0.77)

 < 0.001

1.40 (0.88, 2.23)

0.155

 

 eGFR

per 5 mL/1.73m2

0.85 (0.81, 0.89)

 < 0.001

0.94 (0.88, 1.00)

0.046

 

Prior AIDS diagnoses

 Previous AIDS

 

1.22 (0.91, 1.64)

0.183

0.62 (0.34, 1.14)

0.125

 

Prior non-AIDS diagnoses

 Cardiovascular disease

 

3.74 (1.35, 10.38)

0.011

   

 Non-AIDS defining malignancies

 

2.53 (1.08, 5.90)

0.032

   

Smoking Status

     

 < 0.001

 Never smoked

vs. Curr smoker

1.26 (0.88, 1.81)

0.216

1.30 (0.78, 2.17)

0.322

 

 Former smoker

vs. Curr smoker

1.82 (1.02, 3.27)

0.044

0.87 (0.40, 1.93)

0.739

 

 Unknown smoking status

vs. Curr smoker

0.27 (0.20, 0.36)

 < 0.001

1.24 (0.61, 2.50)

0.551

 

Time Controllers

 Time Enrolled in EuroSIDA

per year longer

1.18 (1.15, 1.21)

 < 0.001

1.17 (1.12, 1.23)

 < 0.001

 

 ART-status

 ART-naïve

vs. ART-experienced

0.10 (0.08, 0.14)

 < 0.001

0.86 (0.46–1.61)

0.634

 
  1. BMI Body mass index; MSM Men who have sex with men; PWID Injecting Drug User; HBsAgHepatitis B surface antigen; HCVAb Hepatitis C antibody; eGFR estimated glomerular filtration rate
  2. Multivariable model includes all variables selected by backward selection that were retained with a p-value less than 0.3 level
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us